Asahi Kasei Pharma: Funding, Team & Investors | Startup Intros

Loading organizations...

Asahi Kasei Pharma: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jan 7, 2026	Mediar Therapeutics	$76.0M Series B	Allan Marchington, Bharat Srinivasa	Alexandria Venture Investments, Longwood Fund
Mar 22, 2023	Curreio	$2.0M Series A	—	3S Capital, Takehiko Sawabe, DOJIN Capital, IKERUNippon Capital Partners, Ono Venture Investment, Kamada, U-Tokyo Entrepreneur Supporter
Dec 1, 2022	Pulmocide	$52.0M Series C	—	Adjuvant Capital, Cystic Fibrosis Foundation, F-Prime Capital, Sabine Dandiguian, Johnson & Johnson Innovation, Longwood Fund, Pictet Alternative Advisors, SR One, SV Health Investors, Vivo Capital
Jun 1, 2022	LUCA Science	$29.0M Series B	4BIO Capital, Shuntaro Kodama	Astellas Venture Management, Axil Capital, Mogrify, Parkwalk Advisors, Remiges Ventures, Sana Capital, Jonathan Milner, Nippon Venture Capital, Nissay Capital, QB Capital/NCB Venture Capital, SMBC Venture Capital
May 1, 2021	Pulmocide	$92.0M Series C	Sabine Dandiguian	Adjuvant Capital, F-Prime Capital, Johnson & Johnson Innovation, Longwood Fund, SR One, SV Health Investors